How Integrin Signaling Drives Stem Cell Fate Into Bone, Fat, and Cartilage

Mesenchymal stem cells (MSCs) are multipotent progenitors found in bone marrow, adipose tissue, dental pulp, and other niches. Their hallmark capacity to differentiate into adipocytes, chondrocytes, and osteoblasts depends critically on crosstalk with the extracellular matrix (ECM), a crosstalk largely mediated by integrins—heterodimeric (α/β subunit) transmembrane receptors that lack intrinsic kinase activity yet orchestrate powerful intracellular signaling cascades.

In adipogenesis, integrin β1 acts as a master regulator of adipocyte differentiation, insulin signaling, and lipid droplet storage in white adipose tissue. Integrin α5β1 amplifies basal insulin receptor phosphorylation and IRS-1 activation. Notably, loss of focal adhesion kinase (FAK) downstream of integrin engagement accelerates adipocyte apoptosis and promotes insulin resistance. Integrin αvβ3 in 3T3-L1 adipocytes mediates IGF-1 signaling through the serpin Serpina3c, while increased collagen-integrin interactions in obese states enhance ERK pathway activation, linking ECM stiffness to dysregulated adipogenesis.

In chondrogenesis, integrins serve as the primary mechanosensors of the pericellular matrix (PCM). Integrin α1β1 is essential for transducing hypoosmotic stress, while α5β1 governs cellular polarization under mechanical stimulation. Mechanical overload activates αVβ3 and αVβ5, upregulating pro-inflammatory mediators IL-1β, TNF-α, MMP-3, and MMP-13—a pathway directly linked to osteoarthritis pathogenesis. ANGPTL2, accumulated in the cartilage ECM, binds integrin α5β1 to further amplify inflammatory cytokine activation. Integrin-β-like 1 (ITGBL1), an endogenous integrin inhibitor, peaks at day 12 of chondrogenic differentiation in hBMSCs and is downregulated in osteoarthritic cartilage, suggesting therapeutic relevance. Downstream, the MAPK-ERK and TGF-β1 pathways coordinate proliferation, ECM synthesis, and tissue homeostasis in cartilage.

In osteogenesis, MSC commitment is initiated by RUNX2, the master transcription factor for bone formation. Integrin signaling reinforces osteoblast differentiation through parallel activation of the Wnt/β-catenin pathway (promoting mineralization) and the FAK/ERK pathway (driving osteogenic gene expression). The review notes that RUNX2 must be downregulated at later stages to allow full osteoblast maturation, illustrating the dynamic, stage-specific nature of integrin-mediated regulation.

Collectively, this review underscores that integrin subtype identity, ECM composition, and mechanical environment collectively determine MSC lineage commitment. It highlights ECM stiffness, specific ligand availability, and growth factor co-signaling (TGF-β, BMP, Wnt) as tunable variables for tissue engineering scaffolds. The authors propose that targeting specific integrin pathways—such as inhibiting ITGBL1 degradation in osteoarthritic joints or modulating FAK activity in adipose dysfunction—represents a promising therapeutic frontier.